Leap reports Phase I data from DKN-01 plus Keytruda arm in esophageal cancer

Leap Therapeutics Inc. (NASDAQ:LPTX) reported data from seven evaluable patients with advanced esophagogastric cancer in

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE